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MLP-Physician Perceptions
MLP* Physician*
Appt Autonomy 82.3 86.4
Appt Practice Scope 94.1 86.9
Effective Communication with Physician 82.4 90
Fairly Compensated 64.7 57.1
Mechanism for Prof Development 58.8 61.1
Appt Amount of Supervision 97.1 85
Appt Amount of Feedback 73.5 76.2
Tolerable Workload 61.8 80.9
Tolerable Emotional Demands 76.5 95.5
* Percentage Who Agree.
Poster Session II S329area, however, the risk of underdosing and its contribution to re-
lapse is unknown. We sought to establish a standard of practice
for dose adjusting chemotherapy in obese patients at our center
which would maximize treatment without excessive toxicity or
underdosing. A survey of practices of dose adjustment by pharma-
cists at 10 transplant centers was undertaken, as well as a review of
more than 25 publications related to transplantation/obesity/and
dose adjustment of chemotherapy. Four centers adjusted all drugs
using the formula of ideal body weight (IBW) + [(actual body
weight – IBW) x 25 or 40%]. Four centers used the same 25 or
40% adjustment only for obese patients (.20-30% IBW). One
center used actual weight or IBW, whichever was less, without
other adjustment. The last center used IBW + 10% of IBW for
dosing, if the difference between actual and IBW was .50 lbs.
None of these institutions addressed the individual drugs physio-
chemical properties such as liphophilicity. The literature review
revealed no consensus beyond the practice of dose adjusting for
actual body weight $120% IBW. With the increasing number
of overweight patients undergoing HSCT, and the limited phar-
macokinetic data available on high dose chemotherapy in over-
weight patients, studies are needed to establish a standard
approach.Figure 1: Implementation of Plerixafor in Planned G-CSF Priming
for First Attempt at Stem Cell Mobilization and Harvesting
Begin GCSF (4 day prime) Check pCD34, Day 4,
continue GCSF
Goal of Colleciton Single Transplant Multiple Transplants
pCD34. 10 pCD34. 20
Apheresis Yield .1.5 x 10(6)
CD341 cells/kg
If Yes Collect to Goal
or yield\0.5 x 10(6)
CD341 cells/kg x2 days
If No and not receiving Plerixafor Add Plerixafor QPM, apheresis next AM
Discuss results with MD
This is to be a figure of an algorithm and does not fit into table form.472
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Mid-level practitioners (MLP’s) are utilized in the inpatient and
ambulatory care settings in many pediatric HSCT programs.
While strict guidelines exist surrounding the training of resident
physicians and fellows, practice guidelines for MLP’s are less well
defined and vary by state or provincial regulations. In an effort to
enhance the MLP-Physician collaborative relationship, we de-
signed a brief survey to determine how MLP’s and physicians per-
ceive the MLP-Physician relationship. On-line surveys were sent to
75 Pediatric Blood and Marrow Transplant Consortium centers.
Physicians and MLP’s received nearly identical surveys; only the
syntax was altered to reflect that the response was MLP opinion
or physician perception. Thirty-six MLP’s and 25 physicians par-
ticipated in the survey.
The survey asked the MLP’s and physicians to define the MLP
clinical role. Results showed that physicians had an excellent under-
standing of this. The physicians acknowledged that the MLP’s play
a role in resident/fellow and nursing education.
Table 1 shows that there was significant agreement between
MLP’s and physicians with respect to autonomy, scope of practice,
communication, and feedback. Both MLP’s and physicians felt that
MLP’s were not compensated fairly. Physicians seem to underesti-
mate the MLP workload and do not fully appreciate the physical
and emotional demands of the MLP role.
There were also misperceptions about how MLP’s spent their
time. For instance, only 28.6% had protected office time, yet 56%
of physicians thought their MLP’s did have this. A majority of phy-
sicians (60%) stated that they had formal sessions with their MLP to
discuss clinical situations and conduct chart reviews/audits. How-
ever, only 38.2% of MLP’s reported that this actually occurred.
Most physicians stated that MLP’s should attend conferences and
encourage the MLP’s to publish. MLP’s concurred with this assess-
ment.
This initial survey suggests that MLP’s and physicians have
a strong collaborative relationship. There responses show that
physicians and MLP’s need to develop strategies for regular struc-
tured feedback. If publishing manuscripts, conducting research or
taking leadership roles in teaching are desired, than more
protected time needs to be provided to the MLP. Physicians
should also recognize that there is a significant physical and emo-
tional aspect to the MLP role. This survey will provide a founda-
tion for future research into optimizing the MLP-Physician
collaboration.473
ALGORITHM FOR NURSING IMPLEMENTATION OF A RISK ADAPTED AP-
PROACH (RAA) TO STEM CELL MOBILIZATION UTILIZING MOZOBIL
(PLERIXAFOR)
Miceli, T.S., Goodew, R.A., Gronseth, M.J., Kaiser, L.L.,
Knudsvig, M.M., Theuer, J.M. Mayo Clinic, Rochester, MN
Autologous stem cell (SC) transplant is an accepted treatment mo-
dality for non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma
(MM). One eligibility requirement to proceed to high dose chemo-
therapy with (SC) rescue is securing adequate SCs (2.0  10(6)
CD34+ cells/kg weight) prior to ablative therapy. Ability to mobilize
SCs is unpredictable. For the pt unable to mobilize SCs with GCSF
alone, treatment options become limited. Plerixafor, recently FDA
approved CXCR4 inhibitor, in combination with GCSF, is proven
to more effectively mobilize SCs than GCSF alone, allowing pts to
receive HD chemotherapy and SC rescue.
The high cost of Plerixafor resulted in the Mayo Clinic – Roches-
ter BMT program implementing a RAA of the medication rather
than upfront use.
Pts were separated into two groups. Pts who previously failed (PF)
to mobilize SCs received upfront use of Plerixafor in combination
with GCSF. GCSF began the morning of Day 1. Plerixafor was in-
troduced the evening of Day 4. SC harvesting began the morning of
Day 5. Collections continued until the pt reached target goal, or, col-
lections were discontinued if two consecutive harvest yields were
\0.5  10(6) CD34+ cells/kg weight.
First time mobilizer criteria for initiating Plerixafor was based on
Day 5 peripheral blood CD34+ (pCD34) evaluation and collection
results. If pCD34 was inadequate on Day 5, Plerixafor was started
that evening and collection Day 6. If harvesting yield was\0.5 or
dropped to\0.5  10(6) CD34+, Plerixafor was instituted. Evalu-
ation of the RAA after 6 months resulted in updates to the ap-
proach. If pCD34 was inadequate on Day 4, Day 1 harvesting
yield \1.5 or yield dropped to \0.5  10(6) CD34+, Plerixafor
was added.
Algorithms were created and revised by nurses, approved by phy-
sicians, for nursing implementation of this RAA (Figure 1), which
continue to guide order creation and pt education.
